Hemophilia Treatment: New Insights Contribute to Minimize or Eliminate Side Effects in the Future

KREMS, Austria - Nov. 22, 2022 - PRLog -- Immune responses against Factor VIII, which is used to treat hemophilia A (bleeding disorder), are influenced by the microenvironment of antigen presenting cells. This is the result of a scientific study conducted in cooperation between the Institute Krems Bioanalytics of IMC University of Applied Sciences Krems and the international pharmaceutical company Takeda, which was recently published in the journal Frontiers in Immunology. In this study, a cell culture model was used to investigate the impact of the microenvironment on factor VIII uptake and processing  in antigen presenting cells. The observed alterations in protein processing might have profound effects on immune responses to FVIII. The novel data provide the basis for the development of future FVIII therapies that elicit minimal immune responses in patients.

Original Publication: Modulating the microenvironment during FVIII uptake influences the nature of FVIII-peptides presented by antigen-presenting cells. Christian Lubich, Katharina N. Steinitz, Brigitte Hoelbl, Thomas Prenninger, Pauline M. van Helden, Markus Weiller, Birgit M. Reipert. Frontiers in Immunology. DOI 10.3389/fimmu.2022.975680

Scientific Contact

Dr. Christian Lubich

Deputy Head of Institute Krems Bioanalytics IMC University of Applied Sciences Krems

Piaristengasse 1

3500 Krems / Austria

T +43-(0)2732-802-179

M +43-(0)664-855 37 10

E christian.lubich@fh-krems.ac.at

W www.krems-bioanalytics.com

Copy Editing & Distribution

PR&D – Public Relations

for Research & Education

Dr. Barbara Bauder

Kollersteig 68

3400 Klosterneuburg / Austria

T +43 664 1576 350

E bauder@prd.at

W http://www.prd.at/